Development of a High-Flow Nasal Cannula and Pharmaceutical Aerosol Combination Device

Spence, Benjamin; Longest, P. Worth; Wei, Xiangyin; Dhapare, Sneha; Hindle, Michael

doi:10.1089/jamp.2018.1488

Cited by 14 publications

(3 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the best case, the NT aerosol loss was 15-20% for the dual prongs with external or internal prongs at a 2 mm insertion depth. Innovative models for administration of dry powders through the nose have been developed and explored and show promise for the future but have yet to advance to clinical trials in infants (Spence et al, 2019;Howe et al, 2021;Howe et al, 2022). More studies on the impact of nasal cannula interfaces on children with pulmonary diseases are warranted.…”

Section: Current and Developing Applications In Clinical Practicementioning

confidence: 99%

Mesh nebulizers enabling transnasal pulmonary delivery of medical aerosols to infants and toddlers: Roles, challenges, and opportunities

Ari

Rubin

Fink

2022

Front. Drug. Deliv.

View full text Add to dashboard Cite

The development of mesh nebulizer technology has expanded the ability to deliver medical aerosols to infants and small children via nasal cannula and prongs. Mesh nebulizers do not require compressed gas to generate aerosols and have a smaller, lighter profile facilitating placement in delivery circuits, unlike ultrasonic nebulizers. Prior to this century, aerosol delivery with the nasal interface to 1–4 kg infants or surrogate animal models was limited to low single-digit deposition. In vitro and animal studies with the enabling mesh technology increase inhaled dose by upwards of 14% when nasal continuous positive airway pressure ventilation is in use. Recently, investigations of transnasal aerosol delivery to the lung have expanded to include nasal cannula interfaces with both high and low flow oxygen administration, nasal continuous positive airway pressure therapy, and nasal noninvasive ventilation in treating respiratory distress, respiratory insufficiency, and acute respiratory failure of infants and toddlers. We will first examine the progression of testing transpulmonary delivery of medical aerosols from in vitro models to in vivo animal and human studies. Then, we will explain current and developing applications in clinical practice to view future directions and opportunities.

show abstract

Section: Current and Developing Applications In Clinical Practicementioning

confidence: 99%

Mesh nebulizers enabling transnasal pulmonary delivery of medical aerosols to infants and toddlers: Roles, challenges, and opportunities

Ari

Rubin

Fink

2022

Front. Drug. Deliv.

View full text Add to dashboard Cite

show abstract

“…Notwithstanding this appreciable properties, the therapeutic use of N/OFQ is strongly compromised due to its low water solubility related to its peptide nature [ 13 , 14 , 15 ]. In fact, reduced protein stability during aerosolization and the pulmonary microenvironment represent major obstacles to its pulmonary administration [ 16 , 17 , 18 ]. This has spurred the development of selective NOP receptor agonists, including non-peptide molecules [ 6 , 19 ] and carrier systems for N/OFQ improving the therapeutic efficacy [ 20 , 21 ].…”

Section: Introductionmentioning

confidence: 99%

Formulation of Solid Lipid Nanoparticles Loaded with Nociceptin/Orphanin FQ (N/OFQ) and Characterization in a Murine Model of Airway Hyperresponsiveness

et al. 2022

View full text Add to dashboard Cite

Asthma is characterized by chronic inflammation and a variable degree of airway hyperresponsiveness (AHR). Our previous papers documented a role for Nociceptin/Orphanin FQ (N/OFQ) and its receptor N/OFQ peptide (NOP) in AHR. Therefore, the aim of this study was to improve the bioavailability of N/OFQ by developing solid lipid nanoparticles (SLNs). N/OFQ-loaded SLNs were prepared by the Quasi Emulsion Solvent Diffusion (QESD) technique and then characterized. Brown Norway rats were sensitized to ovalbumin (OVA) and treated with an intratracheal administration of saline solution or N/OFQ-SLN. Then, 24 h after the last challenge, functional histological and molecular evaluations were performed. SLNs showed a mean diameter of 233 ± 0.03 nm, a polydispersity index (PDI) value around 0.28 ± 0.02 and a drug release percentage of 84.3. The in vitro release of N/OFQ from SLNs showed that the release of the peptide starts already after two hours of incubation. Animals receiving N/OFQ-SLN showed a significative decrease in allergen-induced AHR compared to the control group. These results showed the positive effects of N/OFQ-SLNs on the inflammatory process and on the mechanical properties of the airways, suggesting that the innovative nanotechnological approach may be therapeutically beneficial for asthmatic patients.

show abstract

“…Studies have focused on mathematically modeling heat and water transport in the human respiratory tract (Daviskas et al, 1990;Eisner, 1992;Finlay and Stapleton, 1995;Zhang et al, 2006), or on establishing equations to predict the change in size of hygroscopic inhaled particles (Ferron, 1977;Ferron et al, 1988;Gradon and Podgórski, 1996;Broday and Georgopoulos, 2001;Longest and Hindle, 2012;Boudin et al, 2020). Particle growing in airways has been recently considered as a potential interest to reduce upper airways deposition and increase lung penetration, and deposition when using submicronic aerosols (Longest and Hindle, 2012;Spence et al, 2019). Martin et al (1988) developed a model for particle sizing composed of a trachea and a cascade impactor at 37 • C and either 30%RH or 97.5%RH.…”

Section: Introductionmentioning

confidence: 99%

Humidified and Heated Cascade Impactor for Aerosol Sizing

Majoral

Coates

Pape

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Development of a High-Flow Nasal Cannula and Pharmaceutical Aerosol Combination Device

Cited by 14 publications

References 57 publications

Mesh nebulizers enabling transnasal pulmonary delivery of medical aerosols to infants and toddlers: Roles, challenges, and opportunities

Mesh nebulizers enabling transnasal pulmonary delivery of medical aerosols to infants and toddlers: Roles, challenges, and opportunities

Formulation of Solid Lipid Nanoparticles Loaded with Nociceptin/Orphanin FQ (N/OFQ) and Characterization in a Murine Model of Airway Hyperresponsiveness

Humidified and Heated Cascade Impactor for Aerosol Sizing

Contact Info

Product

Resources

About